// App-Quantinova.ai

5060 : Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models

Researchers

Presenter

  • Allison E. Drew

Principal Investigators

  • Vinny Motwani

  • John E. Campbell

  • Cuyue Tang

  • Jesse J. Smith

  • Richard Chesworth

  • Robert A. Copeland

  • Alejandra Raimondi

  • Scott Ribich

Medical Centers

  • Epizyme, CAMBRIDGE, MA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Tazemetostat

  • Prednisolone

  • Bortezomib

  • Ixazomib

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved